Use of Cox’s Cure Model to Establish Clinical Determinants of Long-Term Disease-Free Survival in Neoadjuvant-Chemotherapy-Treated Breast Cancer Patients without Pathologic Complete Response
Table 2
Patient and tumor characteristics ().
Characteristics
Age, years
Mean ± SD
49.1 ± 9.4
Tumor stage
T1
3 (0.8)
T2
173 (48.2)
T3
116 (32.3)
T4
67 (18.7)
stage
0
176 (49.0)
1
138 (38.4)
2
35 (9.8)
3
10 (2.8)
Clinical stage
IIA
99 (27.6)
IIB
106 (29.5)
IIIA
80 (22.3)
IIIB
65 (18.1)
IIIC
9 (2.5)
Histological grade
G1
20 (5.6)
G2
181 (50.4)
G3
158 (44.0)
Hormone receptor status
Negative
120 (33.4)
Positive
239 (66.6)
PgR status
Negative
200 (55.7)
Positive
159 (44.3)
ER status
Negative
185 (51.5)
Positive
174 (48.5)
HER2 status
Negative
237 (66.0)
Positive
122 (34.0)
NAC regimen
AT
163 (45.4)
AC followed by T
86 (24.0)
CEF followed by T
110 (30.6)
Clinical response
CR
90 (25.1)
PR
215 (59.9)
SD/PD
50 (13.9)
Operation
Lumpectomy
123 (34.3)
Mastectomy
236 (65.7)
Radiotherapy
Yes
239 (66.6)
No
120 (33.4)
Number of lymph node metastases
0
145 (40.4)
1–3
114 (31.8)
≥4
100 (27.8)
Endocrine therapy
TAM, 5 years
140 (39.0)
TAM followed by AI
54 (15.0)
AI, 5 years
33 (9.2)
None
132 (36.8)
ET therapy
No
132 (36.8)
Yes
227 (63.2)
AC: doxorubicin and cyclophosphamide; AI: aromatase inhibitor; AT: doxorubicin and docetaxel; CEF: cyclophosphamide, epirubicin, and 5-fluorouracil; ER: estrogen receptor; HER2: human epidermal growth factor receptor 2; : number of patients; PgR: progesterone receptor; T: taxane (weekly or triweekly paclitaxel or triweekly docetaxel); TAM: tamoxifen. Numbers in parentheses are percentage of patients except for age, which designates mean.
